Massachusetts Financial Services
TRDA icon

Massachusetts Financial Services’s Entrada Therapeutics TRDA Stock Holding History

Massachusetts Financial Services’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-87,387
Closed -$587K – 921
2025
Q2 		$587K Buy
87,387
+1,077
+1% +$8.66K ﹤0.01% 839
2025
Q1 		$780K Buy
86,310
+18,926
+28% +$236K ﹤0.01% 819
2024
Q4 		$1.17M Sell
67,384
-2,010
-3% -$36.4K ﹤0.01% 809
2024
Q3 		$1.11M Buy
+69,394
New +$1.09M ﹤0.01% 791

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Massachusetts Financial Services's TRDA Position: Q3 2025 in Review

Massachusetts Financial Services sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 87,387 shares — an estimated $587K sold.

Massachusetts Financial Services first reported a position in TRDA in Q3 2024 and held it in 4 quarters. The position peaked at $1.17M in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Massachusetts Financial Services reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Massachusetts Financial Services sold 87,387 Entrada Therapeutics shares in Q3 2025, an estimated $587K.
  • Massachusetts Financial Services first reported a position in Entrada Therapeutics in Q3 2024 and held it in 4 quarters.
  • Massachusetts Financial Services's Entrada Therapeutics position peaked at $1.17M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Massachusetts Financial Services's 13F filing for Q3 2025, filed 29 Oct 2025.